A 58-year-old man with a shaved head and an IV pole clicking beside him keeps rubbing at the bridge of his nose, where the skin looks dusky and wet. He has had fever, facial pain, and a thin black crust that seemed small yesterday but now reaches toward his cheek. His wife says he was “fine” until a week of profound weakness after chemotherapy, and now his right eye barely opens. The nurse is waiting for the next order, but the clock is already winning.

— What’s your move? Read on.

Before you read
  • Who needs amphotericin and the OR now, not after imaging?
  • Which immunocompromised patient with fever is sick enough to treat empirically?

When to Think of It

Think of this at the bedside in neutropenia, transplant, prolonged steroids, uncontrolled diabetes, or profound immunosuppression with fever plus focal invasive signs: black eschar, necrotic tissue, pleuritic pain, hemoptysis, focal neuro deficits, sinus/orbital pain, persistent sepsis without bacterial source. Mucormycosis, invasive aspergillosis, candidemia, and endemic fungal syndromes can all present critically, but angioinvasive mold with necrosis is the classic emergency.

Sick or Not Sick

The fork is stable vs. invasive/organ-threatening. Any hemodynamic instability, orbital/CNS involvement, necrosis/eschar, neutropenic sepsis, or pulmonary hemorrhagic lesion = treat as critically ill and escalate immediately.

The First Fifteen Minutes

  • If neutropenic fever or septic shock in a high-risk host → broad-spectrum antipseudomonal antibiotics now: cefepime 2 g IV q8h, or piperacillin-tazobactam 4.5 g IV q6h, or meropenem 1 g IV q8h, because bacterial coinfection is common and death is often bacterial while you chase fungus.
  • If invasive mold strongly suspected (black eschar, orbital/sinus invasion, necrotic lesion, hemoptysis in immunocompromised) → liposomal amphotericin B 5 mg/kg IV daily now; for suspected mucormycosis, many use 5–10 mg/kg IV daily, because it is the fastest reliable broad anti-mold agent and covers Mucorales.
  • If invasive aspergillosis is more likely and mucor less likely → voriconazole 6 mg/kg IV q12h x2 doses, then 4 mg/kg IV q12h (or 200–300 mg PO q12h when appropriate), because it is first-line for Aspergillus and penetrates tissue well.
  • If candidemia or disseminated candidiasis is likely in a sick inpatient → echinocandin now: micafungin 100 mg IV daily, caspofungin 70 mg IV load then 50 mg IV daily, or anidulafungin 200 mg IV load then 100 mg IV daily, because it rapidly clears bloodstream Candida and is fungicidal.
  • If adrenal crisis-like shock with suspected disseminated fungal sepsis and refractory hypotension → fluids, vasopressors, and stress-dose steroids only if otherwise indicated, because the fix is resuscitation plus source control, not empiric steroids.
  • If severe hypoxemia or airway threat from fungal sinus/orbital disease → secure airway early, because edema and necrosis can make later intubation impossible.
  • Consult ENT/ophthalmology/neurosurgery/surgery emergently for biopsy/debridement, because histology and source control are often life-saving.

Definitive Care & Disposition

Definitive treatment is organism- and site-specific: debridement for mucormycosis, antifungal tailoring once cultures/histopathology return, and reversal of immunosuppression when possible. Admit all suspected invasive fungal infections; ICU for shock, respiratory failure, CNS/orbital involvement, or rapidly progressive necrosis. Send blood cultures, fungal markers where useful, CT/MRI for extent, and biopsy any accessible lesion; start therapy before confirmation when suspicion is high.

How This One Kills

The fatal error is dismissing necrotic sinus disease or persistent febrile neutropenia as “just infection” and waiting for culture proof. Angioinvasive fungi thrombose vessels, so tissue dies while the patient looks only mildly worse—until they crash.
The Differential — What Else Looks Like This
  • Bacterial necrotizing soft tissue infection — pain out of proportion and subcutaneous gas point more bacterial; confusing it delays both surgical debridement and the correct antifungal if the lesion is actually invasive mold.
  • Acute bacterial sinusitis/orbital cellulitis — diffuse erythema without black eschar or cranial nerve deficits argues bacterial; missing mucor risks vision loss and brain invasion.
  • Vasculitis or pyoderma gangrenosum — inflammatory ulcers can look necrotic, but immunosuppression plus rapid angioinvasive spread favors fungus; mislabeling as inflammatory disease can worsen outcomes if steroids are given.
  • Melanoma or benign eschar/scab — pigment or crust without systemic illness is misleading; confusion delays biopsy and antifungal therapy.

The Second-Day Story

In older adults, diabetics, or partially treated immunocompromised patients, the “classic” picture softens: fever may be absent, pain may be vague, and the lesion may look like a simple ulcer or sinus headache. The clue is trajectory—rapid progression, tissue duskiness, cranial neuropathies, refractory sepsis, or pleuritic pulmonary disease in the right host should trigger invasive fungal thinking even when the skin or sinus exam seems unimpressive.
Back to Our Patient
Back to our patient: the 58-year-old man with chemotherapy-associated immunosuppression, facial pain, and a black crusting lesion is invasive fungal sinusitis until proven otherwise, most concerning for mucormycosis. His necrotic nasal lesion and orbital involvement put him in the sick category, so the move is immediate liposomal amphotericin B, antipseudomonal antibiotics if febrile/septic, urgent ENT/ophthalmology evaluation for biopsy and surgical debridement, and ICU-level monitoring if unstable. The correct disposition is admission, likely ICU or step-down depending on vitals and extent, with no delay for culture confirmation.
Patient Presentation to Attending
How you’d present this patient on the floor — tight, pertinent positives and negatives, no rambling
“58-year-old man with recent chemotherapy presents with one week of fever and worsening left facial pain. He now has a black necrotic crust on the nasal bridge with progressive periorbital swelling and decreased eye opening; he’s immunocompromised and has been getting weaker, but no trauma or rash elsewhere. On exam he’s febrile and ill-appearing with dusky nasal tissue and orbital edema, concerning for invasive fungal sinusitis with possible orbital extension. I’ve started broad antipseudomonal coverage for neutropenic sepsis risk and am initiating liposomal amphotericin B. ENT and ophthalmology are being consulted now for urgent biopsy and surgical evaluation, and I’m admitting him at ICU level given the risk of rapid progression.”

Study Directive

  • Draw a 3-column table from memory: Candida vs Aspergillus vs Mucorales, with first-line drugs and hallmark clues.
  • Practice a 30-second script for “febrile neutropenia with necrotic facial lesion.”
  • Write the liposomal amphotericin dose from memory, then verify against a reference once.
  • Review when to choose echinocandin vs voriconazole vs amphotericin based on host and anatomy.
  • Commit to memory the trigger for emergent ENT/ophtho consult: necrosis, orbit, or cranial nerve involvement.

Recent Literature